The UK Friedreich Ataxia (FRDA) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Friedreich’s ataxia (FRDA) is the most common inherited ataxia in the UK. FRDA is a genetic, progressive, neurodegenerative movement disorder, that primarily affects the nervous system and the heart with a typical age of onset between 10 and 15 years. The disease begins in childhood resulting in the impairment of muscle coordination that might get worse over time. FRDA is caused by a mutation in a gene labeled FXN and people with FRDA inherit a mutation from each parent, so they have mutations in both copies of their FXN gene. This gene carries the genetic code for the protein ‘frataxin’.
Initial symptoms may include unsteady posture, frequent falling, and progressive difficulty in walking due to impaired ability to coordinate voluntary movements (ataxia). Affected individuals often develop slurred speech (dysarthria), characteristic foot deformities, and an irregular curvature of the spine (scoliosis), and cardiomyopathy. About a third of the people with FRDA develop diabetes mellitus. Estimates from a study suggest that around one person in 30,000 has FRDA. This would mean there are about 2000 people with FRDA in the UK and correspondingly prevalence is about 1.8 per 100,000 in the UK.
Market Growth Drivers
The UK Friedreich ataxia management market is primarily driven by promising pipeline drugs targeting treatment for Friedreich ataxia, an increase in the geriatric population, and the growing application of precision medicine in neurodegenerative diseases. Increasing incidence and prevalence of Friedreich ataxia expected to boost the market growth during the forecast period.
Higher patient population with genetic strains of ataxia, and government initiatives to curb these disorders are anticipated to propel the market during the forecast period and various
support organizations for patient diagnosis & treatment. An increase in the number of drugs in clinical trials and a rise in research & development expenditure for medication treating neurological conditions is projected to drive the market.
However, an increase in the cost of medical treatment, lack of awareness of rare diseases, and occurrence of side effects in related currently available treatments may hamper the Friedreich ataxia treatment market growth.